【醫療民事法】臺灣高等法院高雄分院105年度醫上易字第3號判決評析──藥物不良反應與用藥說明義務【學習式判解評析】   試閱

Comment on Appealed Summary Judgement No. 3 in 2016 in Taiwan High Court Kaohsiung Branch: Adverse Drug Reaction and Duty of Disclosure of Medication

廖建瑜

本件事涉醫師投藥治療卻未向病人說明該藥物之副作用，亦未於事前予以基因檢測，最終病人因藥物過敏致病情惡化，在進行血液透析治療時，因導管脫落出血死亡。本文從醫師說明義務出發，嘗試對比臺、美實務發展經驗，探討說明義務之標準與範圍建構，最後再以藥物基因體學的發展作為切入點，分析基因檢測與告知後同意間的互動關係。

This case is about that a physician medicated a patient without any disclosure of side effects of the medication and any genetic examination. The patient’s condition worsened because of allergies against the medicine and he died eventually because of bleeding which caused by catheters shedding during having a Hemodialysis. Beginning with the duty of disclosure of the physician, the standard of duty of disclosure and its range would be discussed in this paper, comparing with the experience of clinical practice in Taiwan and the US. The development of the pharmacogenomics would in the end be introduced to analyze the relationship between the genetic examination and informed consent.

069-094

告知說明、基因檢測、理性病患、理性醫師、藥品不良反應、disclosure、genetic examination、rational patient、rational physician、adverse drug reaction

月旦醫事法報告

201902 (28期)

元照出版公司

10.3966/241553062019020028006  複製DOI  DOI查詢

【醫療民事法】臺灣高等法院高雄分院105年度醫上易字第3號判決評析──用藥過失責任之形成【學習式判解評析】

溝通關懷於告知說明義務之運用【實務講座】